



PRIOR AUTHORIZATION REQUEST FORM
SPRAVATO™

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

| | | |
|----------------|--------------|-----------------|
| Date: | Member Name: | ID#: |
| DOB: | Gender: | Physician: |
| Office Phone: | Office Fax: | Office Contact: |
| Height/Weight: | HCPCS Code: | |

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Spravato™ (esketamine)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

| Questions | Yes | No | Comments/Notes |
|--|--------------------------|--------------------------|-------------------------------------|
| SPRAVATO™ | | | |
| 1. Is this request for an expedited review? By checking the "Yes" box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy. | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Is the member 18 years of age or older? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Does the member have a diagnosis of moderate to severe major depressive disorder? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 4. If the member is prescribed an antidepressant, has the member been compliant? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. Has the member had an inadequate response to at least an 8-week trial of the maximum tolerated dose of at least 3 (three) antidepressants, each from a different class? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 6. Has the member had an inadequate response to intravenous ketamine treatment? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 7. Has the member had an inadequate response to electroconvulsive therapy (ECT)? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 8. Does the member have a recent history of substance abuse or alcohol use disorder? | <input type="checkbox"/> | <input type="checkbox"/> | |

REAUTHORIZATION

| | | | |
|---|--------------------------|--------------------------|--|
| 1. Is the request for reauthorization of therapy? | <input type="checkbox"/> | <input type="checkbox"/> | |
|---|--------------------------|--------------------------|--|

| | | | |
|--|--------------------------|--------------------------|-------------------------------------|
| 2. If the member is prescribed an antidepressant, has the member been complaint? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Does clinical documentation show continued medical necessity and a positive clinical response? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. | | | |
| Additional information: | | | |
| Physician Signature: | | | |

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM-069
 Origination Date: 07/19/2019
 Reviewed/Revised Date: 01/18/2023
 Next Review Date: 01/18/2024
 Current Effective Date: 04/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.